A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.


Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 4 1 2019
medline: 9 8 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Targeting transferrin receptor 1 (TfR1) with monoclonal antibodies is a promising therapeutic strategy in cancer as tumor cells often overexpress TfR1 and show increased iron needs. We have re-engineered six anti-human TfR1 single-chain variable fragment (scFv) antibodies into fully human scFv

Identifiants

pubmed: 30604643
doi: 10.1080/19420862.2018.1564510
pmc: PMC6512944
doi:

Substances chimiques

Antigens, CD 0
Antineoplastic Agents, Immunological 0
CD71 antigen 0
Receptors, Transferrin 0
Single-Chain Antibodies 0
Tfrc protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

593-605

Références

J Mol Biol. 2000 Sep 1;301(5):1149-61
pubmed: 10966812
J Immunol Methods. 2001 May 1;251(1-2):123-35
pubmed: 11292488
J Immunol Methods. 2001 Aug 1;254(1-2):67-84
pubmed: 11406154
Int Immunol. 2001 Dec;13(12):1551-9
pubmed: 11717196
Science. 2002 Feb 1;295(5556):807-8
pubmed: 11823627
EMBO J. 2002 Feb 15;21(4):590-601
pubmed: 11847107
Blood. 2002 Sep 15;100(6):2087-93
pubmed: 12200371
Physiol Rev. 2003 Jul;83(3):871-932
pubmed: 12843411
Blood. 2004 Mar 1;103(5):1838-45
pubmed: 14592824
Br J Cancer. 2004 Sep 13;91(6):1200-4
pubmed: 15305184
Leuk Res. 2004 Dec;28(12):1329-39
pubmed: 15475075
Cancer Res. 2005 Jan 15;65(2):622-31
pubmed: 15695407
Nat Biotechnol. 2005 Sep;23(9):1126-36
pubmed: 16151406
Blood. 2006 Oct 15;108(8):2745-54
pubmed: 16804109
Clin Immunol. 2006 Nov;121(2):144-58
pubmed: 16904380
J Physiol. 1933 Mar 15;77(4):386-98
pubmed: 16994396
Mol Immunol. 2007 Mar;44(7):1524-34
pubmed: 17045339
Cancer Res. 2007 Feb 1;67(3):1145-54
pubmed: 17283149
Oncogene. 2007 Aug 23;26(39):5828-32
pubmed: 17353899
Mol Immunol. 2007 Jul;44(15):3777-88
pubmed: 17498801
Mol Biol Cell. 2008 Dec;19(12):5490-505
pubmed: 18843053
Cancer Res. 2010 Jul 1;70(13):5497-506
pubmed: 20530676
PLoS One. 2011 Jan 14;6(1):e15921
pubmed: 21264246
Mol Cancer. 2011 Apr 19;10:42
pubmed: 21504579
Sci Transl Med. 2011 May 25;3(84):84ra44
pubmed: 21613623
Blood. 2012 Jul 12;120(2):386-94
pubmed: 22627766
J Biotechnol. 2012 Oct 31;161(3):336-48
pubmed: 22814405
Cancer Res. 1990 May 15;50(10):2936-42
pubmed: 2334894
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12
pubmed: 23636093
Nutrients. 2013 Jul 24;5(8):2836-59
pubmed: 23887041
Methods. 2014 Jan 1;65(1):139-47
pubmed: 24091005
J Exp Med. 2014 Feb 10;211(2):233-44
pubmed: 24470444
MAbs. 2014 Mar-Apr;6(2):502-8
pubmed: 24492305
J Immunol. 1989 Oct 15;143(8):2595-601
pubmed: 2507634
Mol Cancer Ther. 2015 Nov;14(11):2595-605
pubmed: 26358753
Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
Oncotarget. 2017 Jan 24;8(4):6376-6398
pubmed: 28031527
Biochem Biophys Res Commun. 2017 Mar 25;485(1):144-151
pubmed: 28189691
Oncogene. 2017 Jul 20;36(29):4089-4099
pubmed: 28319068
J Immunol. 2017 Jul 15;199(2):418-424
pubmed: 28584008
Biologicals. 2018 Mar;52:1-11
pubmed: 29239840
Cell Rep. 2018 Jan 2;22(1):149-162
pubmed: 29298417
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Mol Cell Biol. 1985 Aug;5(8):1814-21
pubmed: 3018527
Immunol Today. 1997 Dec;18(12):592-8
pubmed: 9425738
Biochemistry. 1998 Jun 2;37(22):7919-28
pubmed: 9609685
Cancer Res. 1998 Sep 1;58(17):3905-8
pubmed: 9731501

Auteurs

Madeline Neiveyans (M)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Rana Melhem (R)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Christophe Arnoult (C)

c CNRS , GICC UMR 7292 , Tours , France.
d Université François Rabelais de Tours , Tours , France.

Thomas Bourquard (T)

e UMR INRA CNRS Physiologie de la reproduction et des comportements, Université François Rabelais de Tours , Nouzilly , France.

Marta Jarlier (M)

b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Muriel Busson (M)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Adrien Laroche (A)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Martine Cerutti (M)

f CNRS, UPS3044 Saint-Christol-Lèz-Alès , France.

Martine Pugnière (M)

g PP2I, Plateforme Protéomique et Interactions Moléculaires , IRCM.

David Ternant (D)

c CNRS , GICC UMR 7292 , Tours , France.
d Université François Rabelais de Tours , Tours , France.
h CHRU de Tours, Department of medical pharmacology , Tours , France.

Nadège Gaborit (N)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Thierry Chardès (T)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Anne Poupon (A)

e UMR INRA CNRS Physiologie de la reproduction et des comportements, Université François Rabelais de Tours , Nouzilly , France.

Valérie Gouilleux-Gruart (V)

c CNRS , GICC UMR 7292 , Tours , France.
d Université François Rabelais de Tours , Tours , France.

Andre Pèlegrin (A)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Marie-Alix Poul (MA)

a IRCM, Institut de Recherche en Cancérologie de Montpellier ; INSERM, U1194, Université de Montpellier, Montpellier , France.
b ICM , Institut régional du Cancer de Montpellier , Montpellier , France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH